• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma.

作者信息

LaCasce Ann S, Bociek R Gregory, Sawas Ahmed, Caimi Paolo, Agura Edward, Matous Jeffrey, Ansell Stephen M, Crosswell Howland E, Islas-Ohlmayer Miguel, Behler Caroline, Cheung Eric, Forero-Torres Andres, Vose Julie, O'Connor Owen A, Josephson Neil, Wang Yinghui, Advani Ranjana

机构信息

Dana-Farber Cancer Institute, Boston, MA, USA.

University of Nebraska Medical Center, Omaha, NE, USA.

出版信息

Br J Haematol. 2020 May;189(3):e86-e90. doi: 10.1111/bjh.16499. Epub 2020 Feb 12.

DOI:10.1111/bjh.16499
PMID:32048731
Abstract
摘要

相似文献

1
Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma.复发或难治性霍奇金淋巴瘤患者接受本妥昔单抗联合苯达莫司汀作为一线挽救治疗的三年疗效
Br J Haematol. 2020 May;189(3):e86-e90. doi: 10.1111/bjh.16499. Epub 2020 Feb 12.
2
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.本妥昔单抗维迪西妥单抗联合苯达莫司汀治疗复发或难治性霍奇金淋巴瘤的国际多中心单臂 1/2 期临床试验。
Lancet Oncol. 2018 Feb;19(2):257-266. doi: 10.1016/S1470-2045(17)30912-9. Epub 2017 Dec 21.
3
The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series.在复发难治性经典型霍奇金淋巴瘤的儿童、青少年和年轻成人中，将苯达莫司汀添加到维布妥昔单抗中可提高完全代谢缓解率：一项回顾性单中心研究系列。
Br J Haematol. 2021 Feb;192(3):e84-e87. doi: 10.1111/bjh.17274. Epub 2021 Jan 10.
4
A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.在干细胞移植前后，对经过大量治疗的难治性或复发性儿童霍奇金淋巴瘤患者采用维布妥昔单抗进行靶向挽救治疗。
Turk J Pediatr. 2019;61(5):671-676. doi: 10.24953/turkjped.2019.05.005.
5
Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.原发性难治性或复发性经典霍奇金淋巴瘤患者应用本妥昔单抗维泊妥珠单抗联合苯达莫司汀桥接自体造血干细胞移植的真实世界疗效。
Ann Hematol. 2020 Oct;99(10):2385-2392. doi: 10.1007/s00277-020-04204-1. Epub 2020 Aug 3.
6
Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma.Brentuximab vedotin 序贯泊马度胺超剂量治疗难治或复发霍奇金淋巴瘤。
Blood Adv. 2019 May 14;3(9):1546-1552. doi: 10.1182/bloodadvances.2019000123.
7
Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.本妥昔单抗维迪西妥单抗联合苯达莫司汀：复发或难治性霍奇金淋巴瘤的高效一线挽救治疗方案。
Blood. 2018 Jul 5;132(1):40-48. doi: 10.1182/blood-2017-11-815183. Epub 2018 Apr 27.
8
Hope After Salvage Therapy Fails: Novel Agents for Relapsed/Refractory Hodgkin Lymphoma.挽救治疗失败后的希望：复发/难治性霍奇金淋巴瘤的新型药物。
Oncology (Williston Park). 2019 May 14;33(5):192-8.
9
Brentuximab vedotin as consolidation after hematopoietic cell transplant for relapsed Hodgkin lymphoma in pediatric patients.在儿科患者中，本妥昔单抗用于造血细胞移植后复发霍奇金淋巴瘤的巩固治疗。
Pediatr Blood Cancer. 2019 Dec;66(12):e27962. doi: 10.1002/pbc.27962. Epub 2019 Aug 20.
10
Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and 'bridge' to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma.与铂类方案相比，本妥昔单抗联合苯达莫司汀作为复发/难治性霍奇金淋巴瘤一线挽救治疗及自体造血干细胞移植“桥梁”的疗效对比
Leuk Lymphoma. 2023 Mar;64(3):742-745. doi: 10.1080/10428194.2022.2164195. Epub 2023 Jan 11.

引用本文的文献

1
When should we use it? The role of brentuximab vedotin in 2024.我们应该何时使用它？2024年本妥昔单抗的作用。
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):511-516. doi: 10.1182/hematology.2024000668.
2
Current perspectives on the management of refractory or relapsed classic hodgkin lymphoma in brazil: Balancing efficacy, safety, and tolerability.巴西难治性或复发性经典霍奇金淋巴瘤管理的现状：平衡疗效、安全性和耐受性。
Oncotarget. 2023 Dec 12;14:977-994. doi: 10.18632/oncotarget.28541.
3
Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy.
免疫治疗时代复发性/难治性经典型霍奇金淋巴瘤的治疗优化
Cancers (Basel). 2023 Sep 11;15(18):4509. doi: 10.3390/cancers15184509.
4
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era.自体造血干细胞移植后进展的 cHL 患者的总生存：新型药物时代的结果。
Blood Adv. 2023 Dec 12;7(23):7295-7303. doi: 10.1182/bloodadvances.2023011205.
5
Advances in the treatment of Hodgkin's lymphoma (Review).霍奇金淋巴瘤治疗的进展（综述）。
Int J Oncol. 2023 May;62(5). doi: 10.3892/ijo.2023.5509. Epub 2023 Apr 7.
6
Advances in the treatment of Hodgkin lymphoma: Current and future approaches.霍奇金淋巴瘤治疗进展：当前与未来的方法
Front Oncol. 2023 Mar 3;13:1067289. doi: 10.3389/fonc.2023.1067289. eCollection 2023.
7
Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma.帕博利珠单抗联合 AVD 方案用于未经治疗的经典型霍奇金淋巴瘤。
Blood. 2023 May 25;141(21):2576-2586. doi: 10.1182/blood.2022019254.
8
Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.基于检查点抑制剂的挽救方案在自体干细胞移植前可改善复发/难治性经典霍奇金淋巴瘤的无事件生存。
Am J Hematol. 2023 Mar;98(3):464-471. doi: 10.1002/ajh.26827. Epub 2023 Jan 11.
9
Incorporating novel agents into frontline treatment of Hodgkin lymphoma.将新型药物纳入霍奇金淋巴瘤的一线治疗。
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):706-716. doi: 10.1182/hematology.2022000363.
10
Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkin's Lymphoma: So Many Options, How to Choose?复发/难治性经典型霍奇金淋巴瘤初始治疗的新型挽救治疗方案：选择众多，如何抉择？
Cancers (Basel). 2022 Jul 20;14(14):3526. doi: 10.3390/cancers14143526.